For patients with triple negative breast cancer, currently undergoing neoadjuvant dd AC, would you consider adding pembrolizumab to weekly paclitaxel based on recent KEYNOTE-522 and continue as adjuvant?

Topics: Breast Cancer • Medical Oncology • Triple negative • Breast Cancer, Non-metastatic

Answer from: Medical Oncologist at Academic Institution

I think the decision should be informed by the degree of response to AC and initial bulk of disease at presentation. In patients who complete the AC portion and still have clinical evidence of substantial residual disease, I would absolutely consider adding pembrolizumab and carboplatin to weekly pa...

Comments

Medical Oncologist at Colorado Permanente Medical Group Hematology & Oncology
Thanks for posing and answering this important que...

Medical Oncologist at Mayo Clinic
This is, of course, a data-free zone and has lots ...

Medical Oncologist at Kettering Cancer Center
Dr. @Roberto A. Leon-Ferre, what is the current ro...

Answer from: Medical Oncologist at Community Practice

There are large differences between GeparNuevo and KEYNOTE-522. GeparNuevo is a phase 2 study with only 174 patients, using nab-paclitaxel without carbo and with dose dense anthracycline regimen. KEYNOTE is a phase 3 study with 1,174 patients, using paclitaxel/carbo and q3week-anthracycline regimen....

Related Questions